The US imposition of a 25% tariff on Indian goods, plus penalties, threatens to increase US healthcare costs, impacting pharmaceutical firms' profits and R&D. While the medical device sector sees potential export benefits if the duty gap with China remains significant, challenges persist due to competition from Indonesia and Vietnam.